Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co in Multiple Transactions

Lilly Endowment Inc. sold a total of 23,084 shares of Eli Lilly & Co common stock in multiple transactions on September 3, 2024.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co, sold 23,084 shares of common stock on September 3, 2024.
• The sales were executed in multiple transactions at weighted average prices ranging from $966.189 to $969.176 per share.
• The total number of shares owned by Lilly Endowment Inc. after these transactions is 96,891,978.
• The transactions were reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing a stock sale by a major shareholder. It is neither positive nor negative in itself, but rather a factual report of transactions.

Industry Context

Form 4 filings are a standard part of regulatory compliance for significant shareholders and provide transparency into their trading activities. This filing indicates a reduction in Lilly Endowment Inc.'s holdings in Eli Lilly & Co.

Comparison to Industry Standards

• Form 4 filings are a standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The transactions are typical for large institutional investors managing their portfolios.
• The reported prices are within the normal trading range for Eli Lilly & Co stock on the transaction date.

Stakeholder Impact

• The sale of shares by a major shareholder could have a minor impact on the stock price, but the effect is likely to be minimal given the relatively small volume of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Lilly Endowment Inc., Eli Lilly & Co, stock sale, Form 4, shareholder, securities transaction